title: Development of multiple abscesses in an HIV/TB co-infected patient after initiation of antituberculous and highly active antiretroviral therapy.
abstract: Since the use of Highly Active Antiretroviral Therapy (HAART) for HIV infection, there have been increasing reports of systemic manifestations of immune restoration. This new clinical syndrome among HIV-infected patients is associated with underlying co-infections with mycobacteria, cytomegalovirus, hepatitis B and C infections, etc.... We report on an HIV/tuberculosis (TB) co-infected patient who developed an immune restoration inflammatory syndrome after initiation of HAART and anti-TB treatment. She developed fever, large abscesses and pleural and peritoneal effusions. Systemic symptoms decreased during corticosteroid treatment, but abscesses only disappeared 8 months after the start of the anti-TB treatment.
authors.affiliation: Departement Klinische Wetenschappen, Instituut voor Tropische Geneeskunde, Nationalestraat 155, B-2000 Antwerpen, België. ebottieau@itg.be
authors.forename: E
authors.initials: E
authors.lastname: Bottieau
authors.forename: A
authors.initials: A
authors.lastname: Noe
authors.forename: E
authors.initials: E
authors.lastname: Florence
authors.forename: B
authors.initials: B
authors.lastname: Ostyn
authors.forename: R
authors.initials: R
authors.lastname: Colebunders
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D000038:Abscess / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects* / Q000379:methods; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001530:Belgium; D004322:Drainage; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology*; D008206:Lymphatic Diseases / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D018570:Risk Assessment; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents